MMRF PRESS RELEASES
Multiple Myeloma Research Foundation to Honor the Legendary Clive Davis at Annual Fall Gala
Onyx Pharmaceuticals President and CEO N. Anthony Coles, M.D., to Receive Corporate Leadership Award
Norwalk, CT — July 16, 2012
The Multiple Myeloma Research Foundation (MMRF) today announced that it will honor five-time Grammy Award winner and noted music industry executive Clive Davis with the Spirit of Hope Award at the 15th anniversary of the annual MMRF Fall Gala on October 27, 2012, in Greenwich, Connecticut. Funds raised at the MMRF Fall Gala will be used to support the development of life-extending treatments for multiple myeloma, an incurable blood cancer.
“Far too many families have been devastated by multiple myeloma and other uncommon cancers that unfortunately have few treatment options available and remain incurable,” said Davis, Chief Creative Officer of Sony Music Entertainment. “The MMRF has a proven track record in bringing patients new treatments that have extended their lives. It is my hope that funds raised during this very impressive event will help the MMRF advance its vital work, benefitting not only patients with multiple myeloma, but, by extension, patients with other uncommon cancers.”
The MMRF Fall Gala is the largest benefit in Fairfield County and is attended by more than 1,200 people, including many celebrities and the nation’s most prominent business executives and high-impact philanthropists. One of the highlights of the evening will be a star-studded tribute concert in Davis’ honor, as was done last year for Stevie Wonder.
“We are thrilled to have Clive Davis, an innovator, a legend, and a true pioneer, join what promises to be an unforgettable night,” said Kathy Giusti, Founder and CEO of the MMRF and a myeloma patient. “Clive’s generous support and that of the artists performing in his honor will help the MMRF continue our dedicated leadership in bringing patients battling orphan cancers like multiple myeloma the treatments they so urgently need.”
The MMRF’s long-standing industry partner, N. Anthony Coles, M.D., President and CEO of Onyx Pharmaceuticals, will also receive a special honor during the night of the Gala – the Corporate Leadership Award. Under Dr. Coles’ leadership, Onyx has worked closely with the MMRF to advance carfilzomib from clinical testing to helping patients with the greatest need access this promising treatment through the Carfilzomib Myeloma Access Program (C-MAP), the first expanded access program for patients with multiple myeloma offered in more than five years. Today, carfilzomib is on the cusp of potential approval as a result of this innovative partnership and the efforts of leading myeloma clinicians around the country.
In addition, Onyx has worked closely with the MMRF to launch the groundbreaking CoMMpassSM study – the first and largest longitudinal study of its kind that aims to predict multiple myeloma disease progression and patients’ response to treatment based on their genomic or molecular profiles.
“The MMRF is widely recognized for its leadership in accelerating the development of transformative treatments for multiple myeloma, and Onyx is proud to consider them among our most trusted and valuable partners,” said Dr. Coles. “We at Onyx have no doubt that the collaborations built by the MMRF will lead to the development of treatment options that significantly extend patients’ lives and vastly improve the outlook of all those living with the disease.”
To reserve a table, donate an auction item or inquire about sponsorship opportunities, please email email@example.com or call 888-584-5463.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti soon after Kathy was diagnosed with multiple myeloma, an incurable blood cancer. The MMRF has taken a bold approach to the pursuit of one singular goal – the faster development of better, more effective treatments – and to this end has played a lead role in the progress made against multiple myeloma, most notably: the development of four new drugs that have doubled life expectancy; the launch of 40 clinical trials of novel and combination treatment through the MMRC where more than 1,000 patients have received treatment; and, advancing five drugs studied through the MMRC’s clinical network into Phase III clinical trials. Of the $200 million the MMRF has raised to support these efforts, an outstanding 90% is directed toward research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted 4-star rating for nine consecutive years – the highest designation for exceptional fiscal responsibility, accountability, and transparency. For more information about the MMRF, visit www.themmrf.org.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2012, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
Anne Quinn Young, MPH